

Haematologica
HAEMATOL/2015/132845
Version 3

Phase II trial of ponatinib in patients with chronic myeloid leukemia
resistant to one previous tyrosine kinase inhibitor

Disclosures: JC receives research support from Ariad, BMS, Novartis, Pfizer and Teva and acts as a consultant for Ariad, BMS, Novartis and Pfizer. EJ acts a consultant for BMS, ARIAD, Pfizer and Teva. HK has received research support from Ariad, BMS, Novartis and Pfizer.

Contributions: DS performed data analysis and co-wrote the manuscript. JC designed the trial, treated patients, performed data analysis and co-wrote the manuscript. HK and EJ treated patients and edited the manuscript. JS collected the data and edited the manuscript. All authors reviewed and approved the final version of the manuscript.